Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Doe C, et al. Among authors: smith gk. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. J Pharmacol Exp Ther. 2007. PMID: 17018693
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA, Cui H, Dowdell SE, Franz RG, Gaitanopoulos DE, Goodman KB, Hilfiker MA, Ivy RL, Leber JD, Marino JP Jr, Oh HJ, Viet AQ, Xu W, Ye G, Zhang D, Zhao Y, Jolivette LJ, Head MS, Semus SF, Elkins PA, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Jung DK, Wright LL, Smith GK, Behm DJ, Doe CP, Bentley R, Chen ZX, Hu E, Lee D. Stavenger RA, et al. Among authors: smith gk. J Med Chem. 2007 Jan 11;50(1):2-5. doi: 10.1021/jm060873p. J Med Chem. 2007. PMID: 17201404
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Goodman KB, Cui H, Dowdell SE, Gaitanopoulos DE, Ivy RL, Sehon CA, Stavenger RA, Wang GZ, Viet AQ, Xu W, Ye G, Semus SF, Evans C, Fries HE, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Jung DK, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D. Goodman KB, et al. Among authors: smith gk. J Med Chem. 2007 Jan 11;50(1):6-9. doi: 10.1021/jm0609014. J Med Chem. 2007. PMID: 17201405
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, Semus SF, Evans C, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D. Sehon CA, et al. Among authors: smith gk. J Med Chem. 2008 Nov 13;51(21):6631-4. doi: 10.1021/jm8005096. Epub 2008 Oct 9. J Med Chem. 2008. PMID: 18842034
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A, Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L. Kazmierski WM, et al. Among authors: smith gk. J Med Chem. 2012 Apr 12;55(7):3021-6. doi: 10.1021/jm201278q. Epub 2012 Apr 3. J Med Chem. 2012. PMID: 22471376
Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.
Li X, Zhang YK, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, Fan D, Liao L, Ni ZJ, White GV, Mordaunt JE, Lazarides LX, Slater MJ, Jarvest RL, Thommes P, Ellis M, Edge CM, Hubbard JA, Somers D, Rowland P, Nassau P, McDowell B, Skarzynski TJ, Kazmierski WM, Grimes RM, Wright LL, Smith GK, Zou W, Wright J, Pennicott LE. Li X, et al. Among authors: smith gk. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3550-6. doi: 10.1016/j.bmcl.2010.04.129. Epub 2010 May 20. Bioorg Med Chem Lett. 2010. PMID: 20493689
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J. Ding CZ, et al. Among authors: smith gk. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7317-22. doi: 10.1016/j.bmcl.2010.10.071. Epub 2010 Oct 21. Bioorg Med Chem Lett. 2010. PMID: 21067923
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
Li X, Liu Y, Zhang YK, Plattner JJ, Baker SJ, Bu W, Liu L, Zhou Y, Ding CZ, Zhang S, Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A. Li X, et al. Among authors: smith gk. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7351-6. doi: 10.1016/j.bmcl.2012.10.075. Epub 2012 Oct 22. Bioorg Med Chem Lett. 2012. PMID: 23142614
Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.
Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J. Li X, et al. Among authors: smith gk. Bioorg Med Chem Lett. 2011 Apr 1;21(7):2048-54. doi: 10.1016/j.bmcl.2011.02.006. Epub 2011 Feb 23. Bioorg Med Chem Lett. 2011. PMID: 21353550
230 results